T cell activation inhibitor, mitochondrial (TCAIM)

T cell activation inhibitor, mitochondrial (TCAIM) is a mitochondrial matrix-localized protein encoded by the TCAIM gene on chromosome 3[2][8]. It comprises several isoforms, the canonical human protein being 496 amino acids in length and highly conserved among vertebrates[2][8]. Its main function appears to be the regulation of T cell apoptosis and tolerance, with evidence showing TCAIM is highly expressed in immune-tolerant states (such as post-transplant tolerance) and may act via dendritic cells and the modulation of mitochondrial signaling[2]. Functional studies suggest TCAIM decreases T cell priming capacity by inhibiting TLR-induced calcium influx and interleukin-2 production, thereby dampening T cell activation[1][7]. It is also implicated as a tumor suppressor in renal carcinoma cells, with expression regulated by vitamin D receptor[3]. Differential expression has been described in disease contexts, including cancer, chronic infection (HIV/AIDS), and metabolic diseases[2][3]. No drugs are currently known to target TCAIM, but it is considered a potential biomarker for transplant tolerance and possibly cancer[2][3][4]. If more specific details are required (structure, sequence, etc.), protein databases like UniProt (Q8N3R3 for human) and Ensembl provide extensive reference data[8].

Other names

C3orf23TOAG1TOAG-1DKFZp313N0621tolerance associated gene-1 proteintolerance associated gene-1T-cell activation inhibitor, mitochondrial